Rigel Pharmaceuticals | RIGL - Trade Debtors


Rigel Pharmaceuticals reported $28.9M in Trade Debtors for its fiscal quarter ending in June of 2024.





Trade Debtors Change Date
Agenus USD 22.44M 1.14M Dec/2025
Amgen USD 9.14B 432M Mar/2026
Anika Therapeutics USD 29.33M 661K Dec/2025
Arrowhead Research USD 15.68M 203.19M Mar/2026
AstraZeneca USD 17.88B 1.17B Mar/2026
BioMarin Pharmaceutical USD 903.91M 4.3M Mar/2026
Bristol-Myers Squibb USD 14.36B 164M Mar/2026
Celldex Therapeutics USD 230K 1.78M Mar/2026
Daiichi Sankyo JPY 695.95B 79.1B Dec/2025
Eli Lilly USD 21.18B 1.02B Mar/2026
Halozyme Therapeutics USD 457.99M 16.72M Mar/2026
Heron Therapeutics USD 89.59M 8.54M Dec/2025
Intrexon USD 1.02M 559K Jun/2024
Ionis Pharmaceuticals USD 74M 8M Mar/2026
Karyopharm Therapeutics USD 26.18M 5.6M Dec/2025
Ligand Pharmaceuticals USD 54.8M 6.25M Mar/2026
MacroGenics USD 10.42M 2.95M Mar/2026
Neurocrine Biosciences USD 768.1M 81.3M Mar/2026
Pfizer USD 16.17B 332M Mar/2026
Regeneron Pharmaceuticals USD 5.73B 10.1M Mar/2026
Rigel Pharmaceuticals USD 28.9M 1.39M Jun/2024
Sangamo BioSciences USD 581K 110K Jun/2024
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
Veracyte USD 50.11M 5.45M Mar/2026